Literature DB >> 19790233

Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia.

A Vikram1, G B Jena, P Ramarao.   

Abstract

BACKGROUND: Obesity, dyslipidemia, Hyperinsulinemia, and insulin resistance (IR) are key features of metabolic syndrome and are considered as risk factors for benign prostatic hyperplasia (BPH) as well as type 2 diabetes. The present study was aimed to determine whether or not IR associated hyperinsulinemia contributes to the BPH.
METHODS: Sprague-Dawley rats (9 weeks) were used in the study. Rats were kept on high fat diet (HFD) for the induction of hyperinsulinemia while hypoinsulinemia was induced by streptozotocin. Effect of HFD feeding on the testosterone-induced prostatic growth was evaluated. Pioglitazone (PG, 20 mg/kg) was used for the reversal of compensatory hyperinsulinemia and to examine the subsequent effect on the prostatic growth.
RESULTS: Prostatic enlargement was observed in the HFD-fed rats. Significant increase in the cell proliferation markers confirmed the occurrence of cellular hyperplasia in the prostate of hyperinsulinemic rat. Enhanced alpha-adrenoceptor mediated contraction in the prostate of HFD-fed rats indicates augmented contractility of the gland. Higher level of phosphorylated-ERK suggests enhanced MEK/ERK signaling. HFD feeding has not led to change in the plasma testosterone level. However, testosterone treatment further augmented the prostatic growth in HFD-fed rats. PG treatment led to improved insulin sensitivity, decreased plasma insulin level and prostate weight, indicating the role of compensatory hyperinsulinemia in the prostate growth.
CONCLUSIONS: The present investigation reports that HFD-feeding induced hyperinsulinemic condition leads to increased cellular proliferation, enhanced alpha-adrenoceptor mediated contraction, and enlargement of the prostate in rats. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19790233     DOI: 10.1002/pros.21041

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  33 in total

1.  Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.

Authors:  Ajit Vikram; Gopabandhu Jena; Poduri Ramarao
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

2.  Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients.

Authors:  Xiaobing Qu; Zhichao Huang; Xianqin Meng; Xiangyu Zhang; Lini Dong; Xiaokun Zhao
Journal:  Int Urol Nephrol       Date:  2014-03       Impact factor: 2.370

3.  The comparison of GLUT-4 and nNOS expression in diabetic and non-diabetic patients with BPH/LUTS.

Authors:  Alper Otunctemur; Huseyin Besiroglu; Murat Dursun; Levent Ozcan; Emre Can Polat; Adnan Somay; Nurver Ozbay; Kutan Ozer; Emin Ozbek
Journal:  Int Urol Nephrol       Date:  2015-04-03       Impact factor: 2.370

Review 4.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

5.  Toll-like receptor 9 regulates metabolic profile and contributes to obesity-induced benign prostatic hyperplasia in mice.

Authors:  Fabiano B Calmasini; Cameron G McCarthy; Camilla F Wenceslau; Fernanda B M Priviero; Edson Antunes; R Clinton Webb
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

6.  The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome.

Authors:  Xiangyu Zhang; Xiaofang Zeng; Lini Dong; Xiaokun Zhao; Xiaobing Qu
Journal:  World J Urol       Date:  2015-04-08       Impact factor: 4.226

Review 7.  Role of interleukins, IGF and stem cells in BPH.

Authors:  Ian D McLaren; Travis J Jerde; Wade Bushman
Journal:  Differentiation       Date:  2011-08-23       Impact factor: 3.880

Review 8.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

9.  Thiazolidinedione and Metformin Use and the Risk of Benign Prostate Hyperplasia in Veterans with Diabetes Mellitus.

Authors:  Harvey J Murff; Christianne L Roumie; Robert A Greevy; Carlos G Grijalva; Adrianna H Hung; Xulei Liu; Marie R Griffin
Journal:  J Mens Health       Date:  2014-12-01       Impact factor: 0.537

Review 10.  Animal models of benign prostatic hyperplasia.

Authors:  Junjie Zhang; Mengda Zhang; Jin Tang; Guangming Yin; Zhi Long; Leye He; Chuanchi Zhou; Lufeng Luo; Lin Qi; Long Wang
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-09-01       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.